Introduction of pneumococcal conjugate vaccine into the public immunization program in South Africa: Translating research into policy

Vaccine

Volumn 30, Issue SUPPL.3, 2012, Pages

  Madhi, Shabir A ^a,b,c   Cohen, Cheryl ^a,d   von Gottberg, Anne ^a,c  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Expanded Programme on Immunization (EPI); HIV; Pneumococcus; South Africa; Streptococcus pneumoniae; Vaccination

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; COTRIMOXAZOLE; NEVIRAPINE; PENICILLIN G; PLACEBO; PNEUMOCOCCUS VACCINE;

ANTIBIOTIC RESISTANCE; ANTIBODY PRODUCTION; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; COMORBIDITY; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH PROGRAM; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MIXED INFECTION; MULTIDRUG RESISTANCE; NASOPHARYNX; NEISSERIA MENINGITIDIS; OUTCOME ASSESSMENT; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROTECTION; REVIEW; SEROTYPE; SINGLE DRUG DOSE; SOUTH AFRICA; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; TREATMENT RESPONSE; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

CARRIER STATE; HEALTH POLICY; HIV INFECTIONS; HUMANS; IMMUNIZATION PROGRAMS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SOUTH AFRICA; VACCINATION; VACCINES, CONJUGATE;

EID: 84865616235     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.05.055     Document Type: Review

References (41)

1. Schoub B.D., Ngcobo N.J., Madhi S. The National Advisory Group on Immunization (NAGI) of the Republic of South Africa. Vaccine 2010, 28 Suppl 1(A31-4):A31-A34.
2. Pneumococcal conjugate vaccine for childhood immunization WHO position paper. Wkly Epidemiol Rec 2007, 82:93-104.
3. Karstaedt A.S., Khoosal M., Crewe-Brown H.H. Pneumococcal bacteremia during a decade in children in Soweto, South Africa. Pediatr Infect Dis J 2000, 19:454-457.
4. Madhi S.A., Petersen K., Madhi A., Wasas A., Klugman K.P. Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children. Pediatr Infect Dis J 2000, 19:1141-1147.
5. Madhi S.A., Petersen K., Madhi A., Khoosal M., Klugman K.P. Increased disease burden and antibiotic resistance of bacteria causing severe community-acquired lower respiratory tract infections in human immunodeficiency virus type 1-infected children. Clin Infect Dis 2000, 31:170-176.
6. Jones N., Huebner R., Khoosal M., Crewe-Brown H., Klugman K. The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population. AIDS 1998, 12:2177-2184.
7. Nyasulu P., Cohen C., de Gouveia L., Feldman C., Klugman K.P., von Gottberg A. Increased risk of death in human immunodeficiency virus-infected children with pneumococcal meningitis in South Africa, 2003-2005. Pediatr Infect Dis J 2011, 30:1075-1080.
8. Huebner R.E., Klugman K.P., Matai U., Eggers R., Hussey G. Laboratory surveillance for Haemophilus influenzae type b, meningococcal, and pneumococcal disease. Haemophilus surveillance working group. S Afr Med J 1999, 89:924-925.
9. Meiring S., Cohen C., Govender N., Keddy K., Msimang V., Quan V., et al. Bacterial and fungal meningitis amongst children <5 years old, South Africa, 2007. S Afr J Epidemiol Infect 2009, 24:30.
10. Nunes M.C., von Gottberg A., de Gouveia L., Cohen C., Moore D.P., Klugman K.P., et al. The impact of antiretroviral treatment on the burden of invasive pneumococcal disease in South African children: a time series analysis. AIDS 2011, 25:453-462.
11. von Gottberg A., de Gouveia L., Quan V., Meiring S., Cohen C., Whitelaw A., et al. Vaccine-preventable invasive pneumococcal disease, South Africa, 2006. S Afr J Epidemiol Infect 2007, 22:95-96.
12. Crowther-Gibson P., Cohen C., Klugman K.P., de Gouveia L., von Gottberg A. Risk factors for multidrug-resistant invasive pneumococcal disease in South Africa, 2003-2008. Poster 12.018. The International Meeting on Emerging Diseases and Surveillance (IMED) 2011, For GERMS-SA.
13. Mbelle N., Huebner R.E., Wasas A.D., Kimura A., Chang I., Klugman K.P. Immunogenicity and impact on nasopharyngeal carriage of a nona-valent pneumococcal conjugate vaccine. J Infect Dis 1999, 180:1171-1176.
14. Huebner R.E., Mbelle N., Forrest B., Madore D.V., Klugman K.P. Immunogenicity after one, two or three doses and impact on the antibody response to co-administered antigens of a nona-valent pneumococcal conjugate vaccine in infants of Soweto, South Africa. Pediatr Infect Dis J 2002, 21:1004-1007.
15. Huebner R.E., Mbelle N., Forrest B., Madore D.V., Klugman K.P. Long-term antibody levels and booster responses in South African children immunized with nona-valent pneumococcal conjugate vaccine. Vaccine 2004, 22:2696-2700.
16. Madhi S.A., Kuwanda L., Cutland C., Klugman K.P. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin Infect Dis 2005, 40:1511-1518.
17. Nurkka A., Ahman H., Korkeila M., Jantti V., Kayhty H., Eskola J. Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2001, 20:25-33.
18. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children, Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000, 19:187-195.
19. Jodar L., Butler J., Carlone G., Dagan R., Goldblatt D., Kayhty H., et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003, 21:3265-3272.
20. Goldblatt D., Southern J., Ashton L., Richmond P., Burbidge P., Tasevska J., et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 2006, 25:312-319.
21. Madhi S.A., Kuwanda L., Cutland C., Holm A., Kayhty H., Klugman K.P. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and -uninfected children. Pediatr Infect Dis J 2005, 24:410-416.
22. Madhi S.A., Adrian P., Kuwanda L., Jassat W., Jones S., Little T., et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 2007, 25:2451-2457.
23. Gray B.M., Converse G.M., Dillon H.C. Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J Infect Dis 1980, 142:923-933.
24. Obaro S.K., Adegbola R.A., Banya W.A., Greenwood B.M. Carriage of pneumococci after pneumococcal vaccination. Lancet 1996, 348:271-272.
25. van Gils E.J., Veenhoven R.H., Hak E., Rodenburg G.D., Bogaert D., Ijzerman E.P., et al. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. JAMA 2009, 302:159-167.
26. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348:1737-1746.
27. Grijalva C.G., Nuorti J.P., Arbogast P.G., Martin S.W., Edwards K.M., Griffin M.R. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007, 369:1179-1186.
28. Flannery B., Heffernan R.T., Harrison L.H., Ray S.M., Reingold A.L., Hadler J., et al. Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann Intern Med 2006, 144:1-9.
29. Simonsen L., Taylor R.J., Young-Xu Y., Haber M., May L., Klugman K.P. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio 2011, 2:e00309-e00310.
30. De Wals P., Robin E., Fortin E., Thibeault R., Ouakki M., Douville-Fradet M. Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec. Canada Pediatr Infect Dis J 2008, 27:963-968.
31. Zhou F., Kyaw M.H., Shefer A., Winston C.A., Nuorti J.P. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med 2007, 161:1162-1168.
32. Klugman K.P., Madhi S.A., Huebner R.E., Kohberger R., Mbelle N., Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003, 349:1341-1348.
33. Klugman K.P., Cutts F., Adegbola R.A., Black S., Madhi S.A., O'Brien K.L., et al. Efficacy and safety: Meta-analysis of the efficacy of conjugate vaccines against invasive pneumococcal disease. Pneumococcal vaccines: the impact of conjugate vaccine 2008, 317-337. ASM Press, Washington, D.C., USA. G.R. Siber, K.P. Klugman, P.H. Makela (Eds.).
34. Cutts F.T., Zaman S.M., Enwere G., Jaffar S., Levine O.S., Okoko J.B., et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005, 365:1139-1146.
35. O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374:893-902.
36. Cherian T., Mulholland E.K., Carlin J.B., Ostensen H., Amin R., de C.M., et al. Standardized interpretation of paediatric chest radiographs for the diagnosis of pneumonia in epidemiological studies. Bull World Health Organ 2005, 83:353-359.
37. Black S.B., Shinefield H.R., Ling S., Hansen J., Fireman B., Spring D., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002, 21:810-815.
38. Lucero M.G., Nohynek H., Williams G., Tallo V., Simoes E.A., Lupisan S., et al. Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial. Pediatr Infect Dis J 2009, 28:455-462.
39. Whitney C.G., Pilishvili T., Farley M.M., Schaffner W., Craig A.S., Lynfield R., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006, 368:1495-1502.
40. World Health Organization Programmes and Projects: Immunization Surveillance, Assessment and Monitoring; WHO Vaccine-Preventable Diseases: Monitoring System 2011, [accessed 08.12.11]. http://apps.who.int/immunization_monitoring/en/globalsummary/countryprofileresult.cfm.
41. Pelton S.I., Weycker D., Klein J.O., Strutton D., Ciuryla V., Oster G. 7-Valent pneumococcal conjugate vaccine and lower respiratory tract infections: effectiveness of a 2-dose versus 3-dose primary series. Vaccine 2010, 28:1575-1582.